:::
黃冠穎

黃冠穎 副教授

  • 研究專長感染免疫學
  • 學術經歷英國牛津大學臨床醫學系博士
  • 聯絡電話886-2312-3456 #288331
  • 電子信箱 arthurhuang1726@ntu.edu.tw

學歷

  • 2011 博士 英國牛津大學臨床醫學系
  • 2002 學士 國立臺灣大學醫學系

經歷

  • 2022-      國立臺灣大學醫學院免疫學研究所  副教授
  • 2022-      國立臺灣大學醫學院附設醫院小兒科  主治醫師
  • 2022-2022  長庚大學醫學系 教授
  • 2021-2022   林口長庚紀念醫院 教授級主治醫師
  • 2018-2022   長庚大學醫學系 副教授
  • 2016-2021   林口長庚紀念醫院 副教授級主治醫師
  • 2012-2016   林口長庚紀念醫院 助理教授級主治醫師

獎項和榮譽

  • 2022   Outstanding Paper Award, Infectious Diseases Society of Taiwan
  • 2021   Young Investigator Award, TienTe Lee Biomedical Foundation
  • 2021   Outstanding Junior Investigator Program, Ministry of Science and Technology
  • 2020   Outstanding Junior Investigator Program, Ministry of Science and Technology
  • 2019    Poster Award in first place, Infectious Diseases Society of Taiwan
  • 2019    Outstanding Paper Award, Infectious Diseases Society of Taiwan
  • 2017    Outstanding Research Paper Award for Attending physician, Chiung-Lin Chen Pediatric Research Award Foundation
  • 2014   Best Research Award, Pediatric Academic Societies and Asian Society for Pediatric Research
  • 2008   Outstanding Research Paper Award for Resident in first place, Infectious Diseases Society of Taiwan

由感染免疫的角度去了解人類適應性免疫反應 (抗原特異性B細胞 、T細胞與抗體) 如何辨識新興或再興起感染症病原體,剖析這些病原體的抗原性是否發生演化,以及分析病原體抗原演化是否對感染症臨床嚴重度或疫情規模產生影響。

黃冠穎副教授研究興趣及方向

  1. Chen CJ et al. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19. Nature Communications 2022;13:5466.
  2. Chen CP et al. Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants. Microbiology Spectrum 2022;10:e0074322.
  3. Huang KA et al. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. Theranostics 2022;12:1-17.
  4. Huang KA*. Structural basis for neutralization of enterovirus. Current Opinion in Virology 2021;51:199-206.
  5. Huang KA et al. Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathogens 2021;17:e1009352.
  6. Huang KA et al. Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71. Nature Communications 2020;11:5253.
  7. Huang KA et al. Emergence of genotype C1 Enterovirus A71 and its link with antigenic variation of virus in Taiwan. PLoS Pathogens 2020;16:e1008857.
  8. Zhou D et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nature Structural & Molecular Biology 2020;27:950-958.
  9. Rijal P et al. Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans. Journal of Virology 2020;94:e01182-19.
  10. Huang KA et al. Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans. Nature Microbiology 2019;4:306-315.
  11. Huang KA et al. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nature Communications 2017;8:762.
  12. Huang KA et al. A Potent Virus-Specific Antibody-Secreting Cell Response to Acute Enterovirus 71 Infection in Children. Journal of Infectious Diseases 2015;212:808-17.
  13. Huang KA et al. Focused antibody response to influenza linked to antigenic drift. Journal of Clinical Investigation 2015;125:2631-45.